Wednesday, July 10, 2019 Daily Archives

Single-use techs are garbage, eventually, and that’s great for biopharma

Biopharma is starting to use single-use technologies more widely but understanding the pros and cons is vital say experts. The key characteristic of any single-use technology is its disposability. Being able to throw away rather than clean equipment after use is a major benefit. Cleaning a stainless steel system takes time and money says Andrew Sinclair, founder of Biopharm Services. “Cleaning a typical stainless steel system can be complex as the equipment and associated pipework needs to be cleaned together…

Investment digest: News from Pfizer, Bayer and Altimmune

Pfizer has completed its $340 million Theracon buy, Bayer pumps $250 million into allogeneic stem cell venture, and Altimmune set to buy NASH drug developer. Welcome to Bioprocess Insider’s investment round-up. First up, Pfizer has added Therachon Holding AG to its business, bringing it assets in development for the treatment of achondroplasia and short bowel syndrome (SBS). The deal, announced in May, saw Pfizer shell out $340 million (€300 million) upfront for the Swiss biotech but the Big Biopharma could…